Login / Signup

Complete response to third-line treatment with trifluridine/tipiracil (TAS-102) in stage IV colon adenocarcinoma.

Celia Lara-MorgaMagda Palka-KotlowskaSara Custodio-CabelloVilma Pacheo-BarciaLuis Cabezón-Gutiérrez
Published in: Exploration of targeted anti-tumor therapy (2023)
A clinical case of a 61-year-old female diagnosed with stage IV right colon adenocarcinoma (unresectable liver and multiple lymph node metastases at the time of diagnosis), Kirsten rat sarcoma viral oncogene homolog ( KRAS ), neuroblastoma rat sarcoma viral oncogene homolog ( NRAS ) and v-raf murine sarcoma viral oncogene homolog B ( BRAF ) wild-type, proficient mismatch repair (pMMR), in whom a complete response to the third-line of systemic treatment with trifluridine/tipiracil (TAS-102) was obtained. The complete response has been maintained for more than 2 years after its suspension.
Keyphrases
  • wild type
  • metastatic colorectal cancer
  • lymph node
  • sars cov
  • locally advanced
  • oxidative stress
  • neoadjuvant chemotherapy
  • replacement therapy
  • sentinel lymph node
  • smoking cessation